561 related articles for article (PubMed ID: 16861088)
1. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL; Baker DE; Setter SM; Keith Campbell R
Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA; Wintle M; Kolterman O
Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
Tzefos M; Olin JL
Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
[TBL] [Abstract][Full Text] [Related]
6. Exenatide.
Keating GM
Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
9. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
11. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
12. Evolution of exenatide as a diabetes therapeutic.
Bhavsar S; Mudaliar S; Cherrington A
Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
14. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
15. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Fineman MS; Bicsak TA; Shen LZ; Taylor K; Gaines E; Varns A; Kim D; Baron AD
Diabetes Care; 2003 Aug; 26(8):2370-7. PubMed ID: 12882864
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
17. Exenatide: from the Gila monster to the pharmacy.
Triplitt C; Chiquette E
J Am Pharm Assoc (2003); 2006; 46(1):44-52; quiz 53-5. PubMed ID: 16529340
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
20. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]